NO20072576L - CTLA-4 antibody and aromatase inhibitor or combination therapy for breast cancer - Google Patents

CTLA-4 antibody and aromatase inhibitor or combination therapy for breast cancer

Info

Publication number
NO20072576L
NO20072576L NO20072576A NO20072576A NO20072576L NO 20072576 L NO20072576 L NO 20072576L NO 20072576 A NO20072576 A NO 20072576A NO 20072576 A NO20072576 A NO 20072576A NO 20072576 L NO20072576 L NO 20072576L
Authority
NO
Norway
Prior art keywords
breast cancer
antibody
aromatase inhibitor
ctla
combination therapy
Prior art date
Application number
NO20072576A
Other languages
Norwegian (no)
Inventor
Jesus Gomez-Navarro
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20072576L publication Critical patent/NO20072576L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Abstract

Oppfinnelsen vedrører administrering av et anti-CTLA4-antistoff, spesielt humane antistoffer mot humant CTLA4, slik som de som har aminosyresekvenser til antistoffer 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9. 1.1 og I ODI (MDX-010), i kombinasjon med en aromatasehemmer, for behandlingen av brystcancer. Mer bestemt vedrører oppfinnelsen administrering av et anti-CTLA4antistoff og eksemestan for behandling av brystcancer.This invention relates to the administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences for antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9. 1.1 and I ODI (MDX-010), in combination with an aromatase inhibitor, for the treatment of breast cancer. More particularly, the invention relates to administration of an anti-CTLA4 antibody and eczema to the treatment of breast cancer.

NO20072576A 2004-11-04 2007-05-21 CTLA-4 antibody and aromatase inhibitor or combination therapy for breast cancer NO20072576L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62485604P 2004-11-04 2004-11-04
PCT/IB2005/003307 WO2006048749A1 (en) 2004-11-04 2005-10-24 Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer

Publications (1)

Publication Number Publication Date
NO20072576L true NO20072576L (en) 2007-08-03

Family

ID=35825412

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072576A NO20072576L (en) 2004-11-04 2007-05-21 CTLA-4 antibody and aromatase inhibitor or combination therapy for breast cancer

Country Status (15)

Country Link
EP (1) EP1819735A1 (en)
JP (1) JP2008518902A (en)
KR (1) KR20070067702A (en)
CN (1) CN101052655A (en)
AR (1) AR053651A1 (en)
AU (1) AU2005300315A1 (en)
BR (1) BRPI0515735A2 (en)
CA (1) CA2586844A1 (en)
IL (1) IL182244A0 (en)
MX (1) MX2007003804A (en)
NO (1) NO20072576L (en)
RU (1) RU2007114111A (en)
TW (1) TW200621804A (en)
WO (1) WO2006048749A1 (en)
ZA (1) ZA200702577B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605796A1 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
US20090117132A1 (en) * 2005-07-07 2009-05-07 Pfizer, Inc. Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
AU2009204194A1 (en) 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN105624193B (en) 2008-09-26 2021-07-13 索元生物医药(美国)有限公司 Recombinant vector
NO2344540T3 (en) 2008-10-02 2018-04-28
EP2456790A1 (en) * 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CN103476943A (en) 2011-03-10 2013-12-25 普罗维克图斯药品公司 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
AU2012302051B2 (en) 2011-08-30 2017-04-27 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
DK2766040T3 (en) * 2011-10-14 2019-07-22 Hoffmann La Roche Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early breast cancer
DK2844282T3 (en) 2012-05-04 2019-07-15 Pfizer PROSTATA ASSOCIATED ANTIGENES AND VACCINE-BASED IMMUNTERAPIREGIMENES
CN103768596B (en) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 For the combination product of oncotherapy, its purposes and correlation technique
JP6419706B2 (en) 2012-10-25 2018-11-07 トカジェン インコーポレーテッド Retroviral vector containing a mini promoter cassette
SG10201707135RA (en) 2013-03-01 2017-10-30 Astex Pharmaceuticals Inc Drug combinations
EA037890B1 (en) * 2013-10-18 2021-06-01 Ридженерон Фармасьютикалз, Инк. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
EP3316685A4 (en) 2015-07-02 2019-03-13 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
AU2016317936A1 (en) 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
CN106883298B (en) 2015-12-16 2021-12-17 上海康岱生物医药技术股份有限公司 Bispecific conjugated antibodies, methods of making and uses thereof
EP3400292B1 (en) 2016-01-08 2020-08-26 Replimune Limited Use of an oncolytic virus for the treatment of cancer
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
TWI784957B (en) 2016-06-20 2022-12-01 英商克馬伯有限公司 Immunocytokines
CN109906088A (en) * 2016-08-26 2019-06-18 奥野哲治 Microvascular blood flow reduces agent and its application
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
FI3589661T3 (en) 2017-03-02 2024-01-31 Genentech Inc Adjuvant treatment of her2-positive breast cancer
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
WO2019025863A2 (en) 2017-08-03 2019-02-07 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
WO2021173870A1 (en) * 2020-02-27 2021-09-02 University Of Washington Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies

Also Published As

Publication number Publication date
ZA200702577B (en) 2008-07-30
EP1819735A1 (en) 2007-08-22
AR053651A1 (en) 2007-05-16
AU2005300315A1 (en) 2006-05-11
WO2006048749A1 (en) 2006-05-11
RU2007114111A (en) 2008-12-10
TW200621804A (en) 2006-07-01
CN101052655A (en) 2007-10-10
JP2008518902A (en) 2008-06-05
KR20070067702A (en) 2007-06-28
MX2007003804A (en) 2007-04-23
BRPI0515735A2 (en) 2011-10-11
CA2586844A1 (en) 2006-05-11
IL182244A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
NO20072576L (en) CTLA-4 antibody and aromatase inhibitor or combination therapy for breast cancer
WO2007113648A3 (en) Ctla4 antibody combination therapy
NO20056236L (en) Treatment with anti-VEGF antibodies
MX2010005651A (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof.
NO20170633A1 (en) Compounds of indolamine-2,3-dioxygenase for use in the treatment of cancer in combination with an anti-PD-1 antibody.
CY1115745T1 (en) COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF OXALIC DISEASES
TW200801042A (en) Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
NO20054769L (en) Substituted phenylalkanoic acids
UA108193C2 (en) APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
CY1114397T1 (en) PHARMACEUTICAL COMPOSITIONS WHICH INCLUDE BACTERIA WHICH DECREASE OXALICS
BR112016029713A8 (en) use of a cross-linked carboxymethylcellulose and use of a gelling agent
CY1113243T1 (en) METHODS OF TREATMENT USING CTLA-4
NO20054958L (en) Substituted amino carboxylic acids
BR112012008624A2 (en) bruton tyrosine kinase inhibitors
MX2011006685A (en) Membrane type-1 matrix metalloprotein inhibitors and uses thereof.
NO20055832L (en) Preparation and use of arylalkyl acid derivatives for the treatment of obesity
NO20062876L (en) Compositions for combined radio and chemotherapy, and methods
UY31114A1 (en) HUMANIZED ANTIBODIES AGAINST AB GLOBULOMER (20-42) AND ITS USES
DK1468014T3 (en) Compositions and Methods for WT1-Specific Immunotherapy
NO20055894L (en) Methods and compositions for the treatment of amyloid-related diseases
NO20070091L (en) Sugar coating and method for this
NO20072951L (en) Treatment of an intestinal adenoma and / or adenocarcinoma by inhibiting Notch pathway activation
EA201000424A1 (en) ANTIBODIES TO IL-23
UA106194C2 (en) Diagnosis and treatment of cancer using anti-ereg antibody

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application